334 related articles for article (PubMed ID: 26338199)
1. Carbon ion beam combined with cisplatin effectively disrupts triple negative breast cancer stem-like cells in vitro.
Sai S; Vares G; Kim EH; Karasawa K; Wang B; Nenoi M; Horimoto Y; Hayashi M
Mol Cancer; 2015 Sep; 14():166. PubMed ID: 26338199
[TBL] [Abstract][Full Text] [Related]
2. Combination of carbon-ion beam and dual tyrosine kinase inhibitor, lapatinib, effectively destroys HER2 positive breast cancer stem-like cells.
Sai S; Kim EH; Vares G; Suzuki M; Yu D; Horimoto Y; Hayashi M
Am J Cancer Res; 2020; 10(8):2371-2386. PubMed ID: 32905515
[TBL] [Abstract][Full Text] [Related]
3. Effects of carbon ion beam alone or in combination with cisplatin on malignant mesothelioma cells
Sai S; Suzuki M; Kim EH; Hayashi M; Vares G; Yamamoto N; Miyamoto T
Oncotarget; 2018 Mar; 9(19):14849-14861. PubMed ID: 29599911
[TBL] [Abstract][Full Text] [Related]
4. Combination of carbon ion beam and gemcitabine causes irreparable DNA damage and death of radioresistant pancreatic cancer stem-like cells in vitro and in vivo.
Sai S; Wakai T; Vares G; Yamada S; Kamijo T; Kamada T; Shirai T
Oncotarget; 2015 Mar; 6(8):5517-35. PubMed ID: 25849939
[TBL] [Abstract][Full Text] [Related]
5. Different effects of carbon ion beams and X-rays on clonogenic survival and DNA repair in human pancreatic cancer stem-like cells.
Oonishi K; Cui X; Hirakawa H; Fujimori A; Kamijo T; Yamada S; Yokosuka O; Kamada T
Radiother Oncol; 2012 Nov; 105(2):258-65. PubMed ID: 23017870
[TBL] [Abstract][Full Text] [Related]
6. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
7. Effects of carbon ion beam on putative colon cancer stem cells and its comparison with X-rays.
Cui X; Oonishi K; Tsujii H; Yasuda T; Matsumoto Y; Furusawa Y; Akashi M; Kamada T; Okayasu R
Cancer Res; 2011 May; 71(10):3676-87. PubMed ID: 21454414
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells.
Tanei T; Choi DS; Rodriguez AA; Liang DH; Dobrolecki L; Ghosh M; Landis MD; Chang JC
Breast Cancer Res; 2016 Jan; 18(1):6. PubMed ID: 26757880
[TBL] [Abstract][Full Text] [Related]
9. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
[TBL] [Abstract][Full Text] [Related]
10. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
[TBL] [Abstract][Full Text] [Related]
11. Inhibiting epidermal growth factor receptor signalling potentiates mesenchymal-epithelial transition of breast cancer stem cells and their responsiveness to anticancer drugs.
Manupati K; Dhoke NR; Debnath T; Yeeravalli R; Guguloth K; Saeidpour S; De UC; Debnath S; Das A
FEBS J; 2017 Jun; 284(12):1830-1854. PubMed ID: 28398698
[TBL] [Abstract][Full Text] [Related]
12. Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity-An Isobolographic Analysis.
Wawruszak A; Luszczki JJ; Kalafut J; Okla K; Halasa M; Rivero-Muller A; Stepulak A
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357442
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines - An Isobolographic Analysis.
Wawruszak A; Luszczki JJ; Grabarska A; Gumbarewicz E; Dmoszynska-Graniczka M; Polberg K; Stepulak A
PLoS One; 2015; 10(11):e0143013. PubMed ID: 26580554
[TBL] [Abstract][Full Text] [Related]
14. Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.
Liu J; Chen X; Ward T; Pegram M; Shen K
Tumour Biol; 2016 Jul; 37(7):9825-35. PubMed ID: 26810188
[TBL] [Abstract][Full Text] [Related]
15. Carbon-Ion Beam Irradiation and the miR-200c Mimic Effectively Eradicate Pancreatic Cancer Stem Cells Under in vitro and in vivo Conditions.
Sai S; Kim EH; Koom WS; Vares G; Suzuki M; Yamada S; Hayashi M
Onco Targets Ther; 2021; 14():4749-4760. PubMed ID: 34556996
[TBL] [Abstract][Full Text] [Related]
16. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
[TBL] [Abstract][Full Text] [Related]
17. Adenovirus-mediated FIR demonstrated TP53-independent cell-killing effect and enhanced antitumor activity of carbon-ion beams.
Kano M; Matsushita K; Rahmutulla B; Yamada S; Shimada H; Kubo S; Hiwasa T; Matsubara H; Nomura F
Gene Ther; 2016 Jan; 23(1):50-6. PubMed ID: 26241176
[TBL] [Abstract][Full Text] [Related]
18. Novel sequential treatment with palbociclib enhances the effect of cisplatin in RB-proficient triple-negative breast cancer.
Huang Y; Wu H; Li X
Cancer Cell Int; 2020; 20():501. PubMed ID: 33061853
[TBL] [Abstract][Full Text] [Related]
19. Glycophenotype of breast and prostate cancer stem cells treated with thieno[2,3-
Mastelić A; Čikeš Čulić V; Režić Mužinić N; Vuica-Ross M; Barker D; Leung EY; Reynisson J; Markotić A
Drug Des Devel Ther; 2017; 11():759-769. PubMed ID: 28352152
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia regulates stemness of breast cancer MDA-MB-231 cells.
Xie J; Xiao Y; Zhu XY; Ning ZY; Xu HF; Wu HM
Med Oncol; 2016 May; 33(5):42. PubMed ID: 27038472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
